PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells

PARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells

Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapies that inhibit PARP proteins which are involved in a variety of cell functions. PARPi may act as modulators of angiogenesis; however, the relationship between PARPi and the vasculogenic mimicry (VM) in breast cancer remains unclear...

Full description

Bibliographic Details
Main Authors: Justine Chivot, Nathalie Ferrand, Aude Fert, Patrick Van Dreden, Romain Morichon, Michèle Sabbah
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:International Journal of Molecular Sciences
Subjects:
PARP inhibitor
vasculogenic mimicry
PTX3
NF-κB signaling
Online Access:https://www.mdpi.com/1422-0067/23/24/16171

Internet

https://www.mdpi.com/1422-0067/23/24/16171

Similar Items